Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Announces Proposed Non-Brokered Private Placement of up to $10 Million

Filing Services Canada August 28, 2018

Theralase(R) Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada August 27, 2018

Theralase Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval

Filing Services Canada August 20, 2018

Breakthrough Cancer Therapy: More Progress in Clinical Study

Jeff Nielson August 16, 2018

Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six

Filing Services Canada August 13, 2018

Theralase Release 2Q2018 Financial Statements

Filing Services Canada July 26, 2018

BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies

Newsfile July 26, 2018

Refined Anti-Cancer Study Yields Breakthrough Result

Jeff Nielson July 17, 2018

Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment

Filing Services Canada July 16, 2018

Theralase Releases AGM Videos

Filing Services Canada June 29, 2018

Theralase Researchers Receive Government Grant

Filing Services Canada June 28, 2018

Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin(R) Based Photo Dynamic Therapy, in Immune Privileged Sites

Filing Services Canada June 22, 2018

Theralase Cancer Therapy: In Search of Medicine’s Holy Grail

Jeff Nielson June 21, 2018

Theralase(R) Demonstrates Significant Advantage in Treatment of Brain Tumours

Filing Services Canada June 11, 2018

Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug

Filing Services Canada June 6, 2018

Theralase Release 1Q2018 Financial Statements

Filing Services Canada May 30, 2018

Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 17, 2018

Theralase Announces Completion of Non-Brokered Private Placement of Units for Aggregate Gross Proceeds of Approximately $1.02 million

Filing Services Canada May 14, 2018

Theralase Announces Proposed Non-Brokered Private Placement of up to $1 Million

Filing Services Canada May 8, 2018